Crystal structure at 1.95 Å resolution of the breast tumour-specific antibody SM3 complexed with its peptide epitope reveals novel hypervariable loop recognition

被引:65
作者
Dokurno, P
Bates, PA
Band, HA
Stewart, LMD
Lally, JM
Burchell, JM
Taylor-Papadimitriou, J
Snary, D
Sternberg, MJE
Freemont, PS
机构
[1] Imperial Canc Res Fund, Mol Struct & Funct Lab, London WC2A 3PX, England
[2] Imperial Canc Res Fund, Biomol Modelling Lab, London WC2A 3PX, England
[3] Imperial Canc Res Fund, Appl Dev Lab, London WC2A 3PX, England
[4] Imperial Canc Res Fund, Epithelial Cell Biol Lab, London WC2A 3PX, England
关键词
anti-tumour antibody; MUC1; breast cancer; peptide epitope; cis-peptide;
D O I
10.1006/jmbi.1998.2209
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The anti-breast tumour antibody SM3 has a high selectivity in reacting specifically with carcinoma-associated mucin. SM3 recognises the core repeating motif (Pro-Asp-ThP-Arg-Pro) of aberrantly glycosylated epithelial mucin MUC1, and has potential as a therapeutic and diagnostic tool. Here we report the crystal structure of the Fab fragment of SM3 in complex with a 13-residue MUC1 peptide antigen (Thr1P-Ser2P-Ala3-Pro4P-Asp5P-Thr6P-Arg7P-Pro8P-Ala9P-Pro10P- Gly11P-Ser12P-Thr13P). The SM3-MUC1 peptide structure was solved by molecular replacement, and the current model is refined at 1.95 Angstrom resolution with an X-factor of 21.3% and R-free 28.3%. The MUC1 peptide is bound both by non-polar interactions and hydrogen bonds in an elongated groove in the antibody-combining site through interactions with Complimentarity Determining Regions (CDRs), three of the light chain (L1, L2, L3) and two of the heavy chain (H1 and H3). The conformation of the peptide is mainly extended with no discernable standard secondary structure. There is a single non-proline cis-peptide bond in H3 (Va195H-Gly96H-Gln97H-Phe98H-Ala101H-Tyr102H) between Gly96H and Gln97H, which appears to play a role in SM3-peptide antigen interactions, and represents the first such example within an antibody hypervariable loop. The SM3-MUC1 peptide structure has implications for rational therapeutic and diagnostic antibody engineering. (C) 1998 Academic Press.
引用
收藏
页码:713 / 728
页数:16
相关论文
共 62 条
[31]  
Hull S R, 1989, Cancer Commun, V1, P261
[32]   THE X-RAY STRUCTURE OF AN ANTITUMOR ANTIBODY IN COMPLEX WITH ANTIGEN [J].
JEFFREY, PD ;
BAJORATH, J ;
CHANG, CY ;
YELTON, D ;
HELLSTROM, I ;
HELLSTROM, KE ;
SHERIFF, S .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (06) :466-471
[33]   WHY ARE PROTEINS O-GLYCOSYLATED [J].
JENTOFT, N .
TRENDS IN BIOCHEMICAL SCIENCES, 1990, 15 (08) :291-294
[34]  
JONES TA, 1994, O MANUAL
[35]  
Kabat E. A., 1991, SEQUENCES PROTEINS I
[36]  
KJELDSEN T, 1988, CANCER RES, V48, P2214
[37]   MOLSCRIPT - A PROGRAM TO PRODUCE BOTH DETAILED AND SCHEMATIC PLOTS OF PROTEIN STRUCTURES [J].
KRAULIS, PJ .
JOURNAL OF APPLIED CRYSTALLOGRAPHY, 1991, 24 :946-950
[38]   PROCHECK - A PROGRAM TO CHECK THE STEREOCHEMICAL QUALITY OF PROTEIN STRUCTURES [J].
LASKOWSKI, RA ;
MACARTHUR, MW ;
MOSS, DS ;
THORNTON, JM .
JOURNAL OF APPLIED CRYSTALLOGRAPHY, 1993, 26 :283-291
[39]   INTERPRETATION OF PROTEIN STRUCTURES - ESTIMATION OF STATIC ACCESSIBILITY [J].
LEE, B ;
RICHARDS, FM .
JOURNAL OF MOLECULAR BIOLOGY, 1971, 55 (03) :379-&
[40]   Three-dimensional structure of an Fab-peptide complex: Structural basis of HIV-1 protease inhibition by a monoclonal antibody [J].
Lescar, J ;
Stouracova, R ;
Riottot, MM ;
Chitarra, V ;
Brynda, J ;
Fabry, M ;
Horejsi, M ;
Sedlacek, J ;
Bentley, GA .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 267 (05) :1207-1222